OP

Oncodesign Precision Medicine at BioTechX Europe 2026

Oct 6–8, 2026 Basel, Switzerland ~3k attendees Website

Oncodesign Precision Medicine takes part in 2 sessions at BioTechX Europe 2026 in Basel. Its program centres on AI in drug discovery and development. The main focus is Nanocyclix, its platform that uses data and AI to design new kinase inhibitors, drugs that block a family of cell-signalling enzymes.

OrganizationBioTechX Europe 2026 Attendance
OP
Oncodesign Precision Medicine
Biotech
French biotech developing kinase inhibitors from its Nanocyclix macrocycle platform, using data-driven AI and machine learning.
Chair
Tue Oct 6
15:25
Chair's remarks
AI in Drug Discovery and Development
Talk
Thu Oct 8
11:30
The (R)evolution of Nanocyclix: A Data-Driven AI/ML Platform for Novel Kinase Inhibitors
AI in Drug Discovery and Development

Explore the full BioTechX Europe 2026 dataset

Get in-depth attendee and institution profiles and research, to plan your meetings in Basel. Leave your work email and we’ll be in touch.

Privacy

Download the full BioTechX Europe 2026 CSV

Leave your work email and we’ll be in touch. The CSV adds attendee names, roles and contact details to the company and session data shown here.

Privacy

Instantly find 20 buyers from Oncodesign Precision Medicine

Get a list of who you should contact, their contact info, and what to say.

Totally free and instant, no sign up necessary!

Not affiliated with or endorsed by Terrapinn or BioTechX. Submit a correction